CStone Pharmaceuticals (HKG:2616)
Hong Kong
· Delayed Price · Currency is HKD 9.49
+0.07 (0.74%)
Apr 29, 2026, 4:08 PM HKT
CStone Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 269.58 | 407.21 | 463.84 | 481.36 | 243.72 | Upgrade
|
| Revenue | 269.58 | 407.21 | 463.84 | 481.36 | 243.72 | Upgrade
|
| Revenue Growth (YoY) | -33.80% | -12.21% | -3.64% | 97.51% | -76.54% | Upgrade
|
| Cost of Revenue | 218.34 | 167.05 | 159.55 | 202.99 | 106.83 | Upgrade
|
| Gross Profit | 51.25 | 240.15 | 304.3 | 278.38 | 136.89 | Upgrade
|
| Selling, General & Admin | 172.36 | 211.58 | 382.06 | 576.36 | 661.38 | Upgrade
|
| Research & Development | 294.71 | 123.93 | 501.4 | 614.16 | 1,305 | Upgrade
|
| Operating Expenses | 467.07 | 335.51 | 883.46 | 1,191 | 1,966 | Upgrade
|
| Operating Income | -415.83 | -95.36 | -579.16 | -912.15 | -1,829 | Upgrade
|
| Interest Expense | -13.27 | -15.17 | -11.82 | -8.48 | -2.24 | Upgrade
|
| Interest & Investment Income | 10.39 | 12.67 | 24.89 | 9.67 | 9.8 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.89 | -2.8 | 20.36 | 61.49 | -69.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 15.16 | 13.44 | 25.71 | 8.71 | 36.02 | Upgrade
|
| EBT Excluding Unusual Items | -406.44 | -87.22 | -520.02 | -840.75 | -1,855 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.71 | 6.36 | 0.3 | -61.93 | -64.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.38 | 178.89 | - | -0.9 | Upgrade
|
| Asset Writedown | -16.8 | -10.73 | -26.4 | - | - | Upgrade
|
| Pretax Income | -423.94 | -91.21 | -367.23 | -902.68 | -1,920 | Upgrade
|
| Income Tax Expense | 13.06 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -437 | -91.21 | -367.23 | -902.68 | -1,920 | Upgrade
|
| Net Income | -437 | -91.21 | -367.23 | -902.68 | -1,920 | Upgrade
|
| Net Income to Common | -437 | -91.21 | -367.23 | -902.68 | -1,920 | Upgrade
|
| Shares Outstanding (Basic) | 1,388 | 1,276 | 1,263 | 1,173 | 1,165 | Upgrade
|
| Shares Outstanding (Diluted) | 1,388 | 1,276 | 1,263 | 1,173 | 1,165 | Upgrade
|
| Shares Change (YoY) | 8.79% | 1.04% | 7.69% | 0.66% | 11.39% | Upgrade
|
| EPS (Basic) | -0.31 | -0.07 | -0.29 | -0.77 | -1.65 | Upgrade
|
| EPS (Diluted) | -0.31 | -0.07 | -0.29 | -0.77 | -1.65 | Upgrade
|
| Free Cash Flow | - | -343.18 | -588.86 | -610.74 | -1,575 | Upgrade
|
| Free Cash Flow Per Share | - | -0.27 | -0.47 | -0.52 | -1.35 | Upgrade
|
| Gross Margin | 19.01% | 58.98% | 65.60% | 57.83% | 56.17% | Upgrade
|
| Operating Margin | -154.25% | -23.42% | -124.86% | -189.49% | -750.64% | Upgrade
|
| Profit Margin | -162.10% | -22.40% | -79.17% | -187.53% | -787.84% | Upgrade
|
| Free Cash Flow Margin | - | -84.28% | -126.95% | -126.88% | -646.26% | Upgrade
|
| EBITDA | -402.53 | -82.06 | -560.24 | -895.41 | -1,821 | Upgrade
|
| EBITDA Margin | -149.31% | -20.15% | -120.78% | -186.01% | - | Upgrade
|
| D&A For EBITDA | 13.3 | 13.3 | 18.93 | 16.74 | 8.76 | Upgrade
|
| EBIT | -415.83 | -95.36 | -579.16 | -912.15 | -1,829 | Upgrade
|
| EBIT Margin | -154.25% | -23.42% | -124.86% | -189.49% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.